Century Capital Management LLC purchased a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 11,665 shares of the specialty pharmaceutical company’s stock, valued at approximately $503,000.

Several other hedge funds also recently modified their holdings of SUPN. Great West Life Assurance Co. Can lifted its position in shares of Supernus Pharmaceuticals by 8.8% during the first quarter. Great West Life Assurance Co. Can now owns 70,594 shares of the specialty pharmaceutical company’s stock worth $2,206,000 after purchasing an additional 5,729 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Supernus Pharmaceuticals by 15.9% during the first quarter. American Century Companies Inc. now owns 285,664 shares of the specialty pharmaceutical company’s stock worth $8,941,000 after purchasing an additional 39,124 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Supernus Pharmaceuticals by 4.9% during the first quarter. Bank of New York Mellon Corp now owns 1,668,864 shares of the specialty pharmaceutical company’s stock worth $52,236,000 after purchasing an additional 78,084 shares during the last quarter. Suntrust Banks Inc. lifted its position in shares of Supernus Pharmaceuticals by 1.8% during the first quarter. Suntrust Banks Inc. now owns 19,913 shares of the specialty pharmaceutical company’s stock worth $622,000 after purchasing an additional 343 shares during the last quarter. Finally, BNP Paribas Arbitrage SA lifted its position in shares of Supernus Pharmaceuticals by 1,265.5% during the first quarter. BNP Paribas Arbitrage SA now owns 138,760 shares of the specialty pharmaceutical company’s stock worth $4,343,000 after purchasing an additional 128,598 shares during the last quarter. 95.38% of the stock is currently owned by institutional investors and hedge funds.

In other news, VP Padmanabh P. Bhatt sold 3,709 shares of Supernus Pharmaceuticals stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $45.23, for a total transaction of $167,758.07. Following the sale, the vice president now directly owns 17,500 shares in the company, valued at approximately $791,525. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 2,556 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, June 23rd. The shares were sold at an average price of $44.90, for a total transaction of $114,764.40. Following the sale, the vice president now owns 24,944 shares in the company, valued at $1,119,985.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 160,000 shares of company stock worth $7,505,574. 6.70% of the stock is owned by company insiders.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) opened at 48.35 on Wednesday. The firm has a 50-day moving average of $43.68 and a 200-day moving average of $37.06. The company has a market cap of $2.45 billion, a PE ratio of 24.39 and a beta of 1.30. Supernus Pharmaceuticals, Inc. has a one year low of $17.25 and a one year high of $49.95.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. The business had revenue of $75.83 million for the quarter, compared to analyst estimates of $68.54 million. On average, analysts predict that Supernus Pharmaceuticals, Inc. will post $1.04 EPS for the current year.

Several equities analysts have recently commented on SUPN shares. Zacks Investment Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price target on the stock in a research report on Thursday, July 13th. Cantor Fitzgerald increased their price target on shares of Supernus Pharmaceuticals from $34.00 to $49.00 and gave the stock a “buy” rating in a research report on Wednesday, July 5th. Jefferies Group LLC increased their price target on shares of Supernus Pharmaceuticals from $45.00 to $51.00 and gave the stock a “buy” rating in a research report on Wednesday, June 28th. BidaskClub cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $47.00 price target (up previously from $36.00) on shares of Supernus Pharmaceuticals in a research report on Tuesday, July 18th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $48.29.

COPYRIGHT VIOLATION NOTICE: “Century Capital Management LLC Purchases New Stake in Supernus Pharmaceuticals, Inc. (SUPN)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/09/13/century-capital-management-llc-purchases-new-stake-in-supernus-pharmaceuticals-inc-supn.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Stock Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.